A new study from Bordeaux University Hospital suggests that many seniors over age 75 might discontinue statin use without a higher mortality rate. For those using the drugs for primary prevention,researchers found no significant increase in strokes or heart attacks over a three-year period.
The 1.5 million seniors facing a prescription dilemma
The scale of this research is significant due to the sheer number of people affected by cardiovascular medication protocols. In the United Kingdom, approximately 8 million adults are currently prescribed statins to manage cholesterol and prevent heart disease. Of that massive group, roughly 1.5 million are over the age of 75.
Statins are typically used for "primary prevention," meaning they are given to patients to prevent an initial cardiovascular event rather than treating one that has already occurred. As the report notes, these medications are often prescribed when lifestyle adjustments alone have failed to manage the risk of heart attack or stroke. this study specifically targets that preventative demographic, questioning whether the long-term benefits justify the continued use in the very elderly.
Comparing the 7.2% death rate of quitters to continuers
The study, which was published in The Lancet Healthy Longevity journal,followed 1,160 adults in France with an average age of 80. Researchers randomly assigned these participants into two groups: those who continued their medication and those who stopped. The medication types included common UK prescriptions such as simvastatin, atorvastatin, and rosuvastatin.
According to the findings, the differences in outcomes between the two groups were not statistically significant. Specifically, the death rate for those who stopped taking statins was 7.2%, compared to 7.9% for those who continued. Similarly, major cardiovascular events occurred in 5% of the group that quit, while the group that continued saw a rate of 4.4%. While heart attacks were slightly higher in the group that stopped (2.1% versus 1.4%), the researchers concluded that discontinuing the drugs was "noninferior" to continuing them.
A 56mg/dl jump in bad cholesterol levels
While the mortality rates remained stable, the physiological impact of stopping the medication was stark. Participants who discontinued their statins saw their low-density lipoprotein (LDL)—often called "bad cholesterol"—rise significantly. On average, LDL levels jumped from 115mg/dl to 171mg/dl within just three months of stopping the treatment.
This 50% increase in bad cholesterol is a major point of clinical concern. High levels of LDL can lead to a buildup in the blood vessels,narrowing the arteries and potentially increasing the long-term risk of heart disease. For context, medical experts generally suggest that healthy LDL levels should remain below 116mg/dl .
The caution urged by Robert Storey and the BHF
Despite the study's findings, medical professionals are warning against immediate changes to medication regimens. robert Storey, a professor of cardiology at the University of Sheffield, noted that the research should not be used to guide the decision-making of the general population in this age group.. He pointed out that the slightly higher risk of heart attacks observed in the study should serve as a note of caution .
There are also several unanswered questions regarding the study's scope. The researchers acknowledged that the 1,160 participants had particularly healthy lifestyles ,which may have skewed the results, and the sample size remains relatively small. Bryan Williams, chief scientific and medical officer at the British Heart Foundation (BHF), added that while the study provides insight, it should not be interpreted as evidence that statins are no longer beneficial for the millions of patients who rely on them as life-saving medicine.
Comments 0